Zobrazeno 1 - 10
of 44
pro vyhledávání: '"J G, Gleason"'
Publikováno v:
Acta Crystallographica Section C Crystal Structure Communications. 46:1244-1248
C26H3405 S, M r --- 458"62, monoclinic, C2/c, a = 26-686 (7), b = 16.479 (4), c = 11.988 (5) A, fl = 105-37 (3), V= 5083.1 (10) A 3, Z = 8, Dm (flotation in aqueous ZnC12) = 1.20 (2), Dx = 1.198 g cm -3, A(MoK~)=0.71073/ ~, /z = 1-516cm -1, F(000) =1
Autor:
E F, Nemeth, E G, Delmar, W L, Heaton, M A, Miller, L D, Lambert, R L, Conklin, M, Gowen, J G, Gleason, P K, Bhatnagar, J, Fox
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 299(1)
Despite the discovery of many ions and molecules that activate the Ca2+ receptor, there are no known ligands that block this receptor. Reported here are the pharmacodynamic properties of a small molecule, NPS 2143, which acts as an antagonist at the
Autor:
S S, Tian, P, Lamb, A G, King, S G, Miller, L, Kessler, J I, Luengo, L, Averill, R K, Johnson, J G, Gleason, L M, Pelus, S B, Dillon, J, Rosen
Publikováno v:
Science (New York, N.Y.). 281(5374)
A nonpeptidyl small molecule SB 247464, capable of activating granulocyte-colony-stimulating factor (G-CSF) signal transduction pathways, was identified in a high-throughput assay in cultured cells. Like G-CSF, SB 247464 induced tyrosine phosphorylat
Autor:
D P, Brooks, P D, dePalma, M, Gellai, P, Nambi, E H, Ohlstein, J D, Elliott, J G, Gleason, R R, Ruffolo
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 271(2)
Endothelin (ET) is a potent vasoconstrictor that has been implicated in the pathogenesis of acute renal failure (ARF). In order to investigate the potential role of ET in ARF in the dog, the effect of a mixed ETA and ETB receptor antagonist, (+/-)-SB
Autor:
E H, Ohlstein, G R, Beck, S A, Douglas, P, Nambi, M A, Lago, J G, Gleason, R R, Ruffolo, G, Feuerstein, J D, Elliott
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 271(2)
The pharmacological characterization of SB 209670, a highly potent nonpeptide endothelin ETA/ETB receptor antagonist was performed. SB 209670 produced concentration-dependent, parallel rightward shifts in the ET-1 concentration-response curves in the
Autor:
P, Nambi, N, Elshourbagy, H L, Wu, M, Pullen, E H, Ohlstein, D P, Brooks, M A, Lago, J D, Elliott, J G, Gleason, R R, Ruffolo
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 271(2)
The effect of a series of endothelin (ET) receptor antagonists, including the novel nonpeptide receptor antagonist, SB 209670, on [125I]ET-1 binding to human ET receptors (ETA and ETB) cloned and stably expressed in Chinese hamster ovary cells was st
Autor:
S K, Thompson, K H, Murthy, B, Zhao, E, Winborne, D W, Green, S M, Fisher, R L, DesJarlais, T A, Tomaszek, T D, Meek, J G, Gleason
Publikováno v:
Journal of medicinal chemistry. 37(19)
The rational design and synthesis of a highly potent inhibitor of HIV-1 protease have been accomplished. The inhibitor, SB 206343, is based on a model derived from the structure of the MVT-101/HIV-1 protease complex and contains a 4(5)-acylimidazole